|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 1998
Clinical Trial |
Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation
The effects of usual or low doses of inhaled corticosteroids on airway mucosal inflammation have not yet been examined. We therefore, compared the effects of inhaled beclomethasone dipropionate (BDP) 336 microg x day(-1) on asthma control outcomes and markers of airway inflammation. Twenty-four adult subjects with mild and moderate asthma were randomized to receive either BDP or placebo for four weeks; then subjects entered a single blind four week placebo run-in period. We found that the BDP group had significantly greater improvements in forced expiratory volume in one second (FEV1), morning peak flow, and rescue salbutamol use than the placebo-treated group. The improvement in FEV1 largely reversed one week after treatment was stopped. The decrease in the median percentage of eosinophils in induced sputum in the BDP group from 3.8% to 3.4% was not significant, but because eosinophils increased from 8.4% to 12.7% in the placebo group, there was a significant difference between treatment groups (p=0.03). There was no significant difference between groups during treatment in the levels of eosinophil cationic protein (ECP), tryptase mucin-like glycoprotein, or fibrinogen in induced sputum. The change in FEV1 in the BDP group did not correlate significantly with the change in eosinophil percentage or ECP levels. We concluded that four weeks of treatment with inhaled beclomethasone dipropionate 336 microg x day(-1) was associated with significant improvements in peak flow, forced expiratory volume in one second, and rescue salbutamol use in asthmatic subjects but was not associated with large reductions in markers of eosinophilic inflammation, bronchovascular permeability, or mucus hypersecretion.
This article has been cited by other articles:
|
|
 |
|
  H. A. Boushey Daily Inhaled Corticosteroid Treatment Should Not Be Prescribed for Mild Persistent Asthma Am. J. Respir. Crit. Care Med., August 15, 2005; 172(4): 412 - 414. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Foresi, B. Mastropasqua, A. Chetta, R. D'Ippolito, R. Testi, D. Olivieri, and A. Pelucchi Step-Down Compared to Fixed-Dose Treatment With Inhaled Fluticasone Propionate in Asthma Chest, January 1, 2005; 127(1): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-M. Lee, J.-S. Park, J.-H. Hwang, S.-W. Park, S.-t. Uh, Y.-H. Kim, and C.-S. Park High-Resolution CT Findings in Patients With Near-Fatal Asthma: Comparison of Patients With Mild-to-Severe Asthma and Normal Control Subjects and Changes in Airway Abnormalities Following Steroid Treatment Chest, December 1, 2004; 126(6): 1840 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Chanez, A. Bourdin, I. Vachier, P. Godard, J. Bousquet, and A. M. Vignola Effects of Inhaled Corticosteroids on Pathology in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 184 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P-R. Burgel, L.O. Cardell, I.F. Ueki, and J.A. Nadel Intranasal steroids decrease eosinophils but not mucin expression in nasal polyps Eur. Respir. J., October 1, 2004; 24(4): 594 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. O'Sullivan, L. Cormican, M. Murphy, L. W. Poulter, and C. M. Burke Effects of Varying Doses of Fluticasone Propionate on the Physiology and Bronchial Wall Immunopathology in Mild-to-Moderate Asthma Chest, December 1, 2002; 122(6): 1966 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bacci, A. Di Franco, M.L. Bartoli, S. Carnevali, S. Cianchetti, F.L. Dente, D. Giannini, B. Vagaggini, L. Ruocco, and P.L. Paggiaro Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma Eur. Respir. J., July 1, 2002; 20(1): 66 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Leader of the Working Group:, J.C. Kips, Members of the Working Group:, M.D. Inman, L. Jayaram, E.H. Bel, K. Parameswaran, M.M.M. Pizzichini, I.D. Pavord, R. Djukanovic, et al. The use of induced sputum in clinical trials Eur. Respir. J., July 1, 2002; 20(37_suppl): 47S - 50s. [Full Text] [PDF]
|
|
|
|
 |
|
 G W Chalmers, K J Macleod, S A Little, L J Thomson, C P McSharry, and N C Thomson Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma Thorax, March 1, 2002; 57(3): 226 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W Anees, V Huggins, I D Pavord, A S Robertson, and P S Burge Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants Thorax, March 1, 2002; 57(3): 231 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. FAHY, H. A. BOUSHEY, S. C. LAZARUS, E. A. MAUGER, R. M. CHERNIACK, V. M. CHINCHILLI, T. J. CRAIG, J. M. DRAZEN, J. G. FORD, J. E. FISH, et al. Safety and Reproducibility of Sputum Induction in Asthmatic Subjects in a Multicenter Study Am. J. Respir. Crit. Care Med., May 1, 2001; 163(6): 1470 - 1475. [Abstract] [Full Text]
|
|
|
|
|
|
E. Rosi and G. Scano Association of sputum parameters with clinical and functional measurements in asthma Thorax, March 1, 2000; 55(3): 235 - 238. [Full Text]
|
|
|
|
|
|
S. PEDERSEN Why Does Airway Inflammation Persist? Is It Failure to Treat Early? Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): S182 - 185. [Full Text] [PDF]
|
|
|
|
|
|
J. L. FAUL, E. A. DEMERS, C. M. BURKE, and L. W. POULTER The Reproducibility of Repeat Measures of Airway Inflammation in Stable Atopic Asthma Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1457 - 1461. [Abstract] [Full Text]
|
|
|
|
|
|
F. E. HARGREAVE and R. LEIGH Induced Sputum, Eosinophilic Bronchitis, and Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): S53 - 57. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |